Trials / Recruiting
RecruitingNCT06477237
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Huabo Biopharm Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HB0017 Q4W | HB0017 at W0,1,2,4,8+HB0017Q4W |
| BIOLOGICAL | HB0017 Q8W | HB0017 at W0,1,2,4,8+HB0017Q8W |
| BIOLOGICAL | placebo | placebo at W0,1,2,4,8+HB0017Q4W |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2024-08-01
- Completion
- 2025-12-01
- First posted
- 2024-06-27
- Last updated
- 2024-06-27
Locations
44 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06477237. Inclusion in this directory is not an endorsement.